Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

Bishnoi, Rohit; Bajwa, Ravneet; Franke, Aaron J.; Skelton, William Paul; Wang, Yu; Patel, Niraj M.; Slayton, William Birdsall; Zou, Fei; Dang, Nam H.

doi:10.1186/s40164-017-0087-0

Experimental Hematology & Oncology

Table 1 Study population characteristics with univariate analysis

From: Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

Variables	Sub-types	n	Percentage	p-value	Hazard ratios	95% confidence limits
Gender	Males	88	62.4
Gender	Females	53	37.6	0.0427	0.553	0.311–0.981
Race	White	101	71.6	0.1314	1.670	0.858–3.252
	Black or African American	25	17.7	0.8428	0.930	0.452–1.911
	Asian	4	2.8	0.5190	0.521	0.072–3.776
	Native Hawaiian or other Pacific Islander	1	0.7	0.9862	0.000	0.000–0.000
	Other/Unknown	10	7.1	0.1292	0.216	0.030–1.564
Transplant organ	Liver	49	34.8	0.0023	0.357	0.184–0.693
	Kidney	31	22.0	0.9348	0.973	0.502–1.886
	Heart	30	21.3	0.9153	0.967	0.517–1.809
	Lung	17	12.1	< .0001	4.380	2.327–8.245
	Kidney and pancreas	3	2.1	0.8666	0.844	0.116–6.116
	BMT	11	7.8	0.0746	2.197	0.925–5.219
Age group at transplant	Pediatrics (< 18 years)	58	41.1	< .0001	0.207	0.105–0.407
	Adults (18–64 years)	74	52.5	< .0001	3.316	1.836–5.990
	Elderly (> 65 years)	9	6.4	0.0472	2.573	1.012–6.545
Age group at PTLD diagnosis	Pediatrics (< 18 years)	54	38.3	< .0001	0.241	0.123–0.473
	Adults (18–64 years)	64	45.4	0.0633	1.657	0.972–2.823
	Elderly (> 65 years)	23	16.3	< .0001	3.543	1.894–6.628
PTLD onset time	Early (less than 1 year)	35	24.8	0.8426	0.939	0.502–1.754
	Late (after 1 year)	73	51.8	0.7821	0.928	0.546–1.577
	Very late (after 10 years)	33	23.4	0.5787	1.196	0.636–2.246
Recipient serostatus at transplant	EBV positive	82	58.2	0.0127	2.666	1.233–5.765
Recipient serostatus at transplant	CMV positive	56	39.7	0.8110	1.072	0.606–1.896
Acute rejection episodes before PTLD	Present	62	44.0	0.0961	1.580	0.922–2.708
Acute rejection episodes before PTLD	Multiple episodes	23	16.3	0.0073	2.243	1.244–4.046
B-symptoms	Present	68	48.2	0.3214	1.326	0.759–2.316
B-symptoms	Absent	73	51.8
ECOG status	0–2	128	90.8	< .0001	0.183	0.0910.368
ECOG status	3–4	11	7.8
Ann-Arbor stage	I	43	30.5
	II	24	17.0
	III	14	9.9
	IV	55	39.0
	Unknown	5	3.5
	Limited stage (I–II)
	Advanced stage (III–IV)			0.1997	1.447	0.823–2.543
Extra nodal disease	Yes	98	69.5	0.3704	1.345	0.703–2.570
	No	36	25.5
	Unknown	7	5.0
More than 1 extra-nodal site	Yes	32	22.7	0.1903	1.517	0.813–2.829
CNS	Yes	5	3.5	0.7181	1.240	0.386–3.979
Bone marrow	Yes	13	9.2	0.0423	2.184	1.027–4.643
Allograft	Yes	15	10.6	0.4536	1.355	0.612–3.001
GI tract	Yes	38	27	0.4692	0.788	0.414–1.501
Albumin at diagnosis	Normal	67	47.5	0.4515	0.809	0.466–1.405
	Low	65	46.1
	Unknown	9	6.4
CD20 status	Positive	104	73.8	0.9303	1.039	0.438–2.464
	Negative	18	12.8
	Unknown	19	13.5
Tumor EBER status	Positive	78	55.3	0.8760	0.954	0.531–1.714
	Negative	49	34.8
	Unknown	14	9.9
IPI score	0–2	84	59.6
	3–5	41	29.1	0.0422	1.843	1.022–3.324
	Unknown	16	11.3

Statistically significant P values (< 0.05) are shown in italics

Back to article page

ISSN: 2162-3619

Contact us

Submission enquiries: journalsubmissions@springernature.com